The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial.
Eur Radiol
; 26(8): 2798-807, 2016 Aug.
Article
en En
| MEDLINE
| ID: mdl-26560727
ABSTRACT
OBJECTIVES:
To characterize a radiogenomic risk score (RRS), a previously defined biomarker, and to evaluate its potential for stratifying radiological progression-free survival (rPFS) in patients with metastatic renal cell carcinoma (mRCC) undergoing pre-surgical treatment with bevacizumab.METHODOLOGY:
In this IRB-approved study, prospective imaging analysis of the RRS was performed on phase II clinical trial data of mRCC patients (n = 41) evaluating whether patient stratification according to the RRS resulted in groups more or less likely to have a rPFS to pre-surgical bevacizumab prior to cytoreductive nephrectomy. Survival times of RRS subgroups were analyzed using Kaplan-Meier survival analysis.RESULTS:
The RRS is enriched in diverse molecular processes including drug response, stress response, protein kinase regulation, and signal transduction pathways (P < 0.05). The RRS successfully stratified rPFS to bevacizumab based on pre-treatment computed tomography imaging with a median progression-free survival of 6 versus >25 months (P = 0.005) and overall survival of 25 versus >37 months in the high and low RRS groups (P = 0.03), respectively. Conventional prognostic predictors including the Motzer and Heng criteria were not predictive in this cohort (P > 0.05).CONCLUSIONS:
The RRS stratifies rPFS to bevacizumab in patients from a phase II clinical trial with mRCC undergoing cytoreductive nephrectomy and pre-surgical bevacizumab. KEY POINTS ⢠The RRS SOMA stratifies patient outcomes in a phase II clinical trial. ⢠RRS stratifies subjects into prognostic groups in a discrete or continuous fashion. ⢠RRS is biologically enriched in diverse processes including drug response programs.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Renales
/
Tomografía Computarizada por Rayos X
/
Medición de Riesgo
/
Bevacizumab
/
Neoplasias Renales
/
Nefrectomía
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Eur Radiol
Asunto de la revista:
RADIOLOGIA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Estados Unidos